Cutaneous squamous cell carcinoma is a common skin malignancy arising from keratinocytes and is the second most common cutaneous malignancy in the United States. Risk factors include ultraviolet radiation, immunosuppression, older age, and fair skin. Although metastasis is uncommon, timely diagnosis and treatment are important to reduce morbidity and mortality.
DelveInsight pipeline reports reveal robust clinical development across three cancer indications, with 45+ companies advancing cutaneous squamous cell carcinoma therapies, 70+ companies developing liver cancer treatments, and multiple hepatocellular carcinoma candidates receiving FDA designations in 2025-2026.
Secondary analysis of KEYNOTE-716 trial finds adjuvant pembrolizumab improves recurrence-free survival in stage IIB/IIC melanoma without increasing new primary melanoma risk, while reducing non-melanoma skin cancers.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07602842 |
A Study of IDP-001 in Advanced or Metastatic Solid Tumors |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07426484 |
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy |
NOT_YET_RECRUITING | PHASE4 |
| NCT07402616 |
Ex Vivo Cutaneous SCC |
RECRUITING | NA |
| NCT07288073 |
TIL Therapy in cSCC and MCC |
RECRUITING | PHASE2 |
| NCT06875609 |
ctDNA in Cutaneous Squamous Cell Carcinoma |
RECRUITING | |
| NCT06823479 |
Towards Cure Via Only Ultra-short ICB in CSCC |
RECRUITING | PHASE2 |
| NCT06659146 |
Thermotherapy in Addition to SOC Palliative Radiotherapy |
RECRUITING | NA |
| NCT06644079 |
Window of Opportunity Study of Topical Tranexamic Acid for Cutaneous Squamous Cell Carcinoma |
WITHDRAWN | PHASE2 |
| NCT06577311 |
Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis) |
RECRUITING | PHASE2 |
| NCT06567314 |
Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma |
RECRUITING | PHASE2 |
